Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001213900-21-001429
Filing Date
2021-01-11
Accepted
2021-01-11 16:10:25
Documents
1
Period of Report
2021-01-07

Document Format Files

Seq Description Document Type Size
1 ownership.html 4  
1 ownership.xml 4 3905
  Complete submission text file 0001213900-21-001429.txt   5350
Mailing Address 880 3RD AVENUE, 12TH FLOOR NEW YORK NY 10022
Business Address 880 3RD AVENUE, 12TH FLOOR NEW YORK NY 10022 646 876 3459
RELMADA THERAPEUTICS, INC. (Issuer) CIK: 0001553643 (see all company filings)

EIN.: 455401931 | State of Incorp.: NV | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O ALLOGENE THERAPEUTICS, INC. 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address
SCHMIDT ERIC THOMAS (Reporting) CIK: 0001754403 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39082 | Film No.: 21520908